+19.4%
AKAM vs MRNA
+945.0%
-925.6%
-46.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.7% | +13.1% | -13.8% | -0.9% |
| 7D | -12.4% | +20.6% | -33.1% | -12.6% |
| 30D | -20.4% | +27.1% | -47.6% | -20.7% |
| 3M | -30.3% | +353.4% | -383.7% | -32.2% |
| 6M | -18.8% | +446.3% | -465.0% | -25.2% |
| YTD | -1.5% | +776.2% | -777.7% | -12.6% |
| 1Y | +19.4% | +987.9% | -968.5% | +2.3% |
| All | +19.4% | +945.0% | -925.6% | +2.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling